PAB

0.00%

0.7¢ patrys limited

Ann: Investor update, page-26

First 26 Last

Share
Profile

Follow
Akki

35,729 Posts.

554

05/08/20

13:14

Post #: 46318577
Share

Originally posted by Akki ↑

That was a good juicy update ... wedge will break soon - it loves that high....

Still probably more likely on base once stock is allocated

but who knows tricky position, wedge says sooner and too late once allocated.

Patrys’ lead asset PAT-DX1 exploits the DNA Damage Response (DDR) mechanism to block DNA repair and preferentially kill cancer cells. In animal models, PAT-DX1 has shown efficacy in killing cancer cells with a range of DDR gene mutations such as BRCA2 and PTEN – and importantly it does not kill cells without those mutations (i.e. healthy cells). This could be a game changer in the oncology space. PAT-DX1 is the only known antibody to have shown efficacy as a single agent via the synthetic lethality model. Unlike other antibodies and 98% of small molecules, it can also cross the blood brain barrier (BBB), which provides all-important access to cancer cells in the central nervous system.

Synthetic lethality has also attracted a lot of deal making attention in the past few weeks. In May 2020, Bristol Myers Squibb closed a US$65M deal with Repare Therapeutics for access to its DDR technology platform, and Glaxo Smith Kline inked a deal with IDEAYA Biosciences for three discovery-stage synthetic lethality assets (US$100M upfront, US$20M equity investment, potential development and regulatory milestone payments of around US$465-485M and commercial milestones of US$475M for two of the more advanced programs). It is clear that big pharma and big biotech are increasingly compelled by the elegance of synthetic lethality and DDR therapeutic approaches for treating a range of tumours.

Patrys is in the enviable position of developing a novel therapeutic that combines the established safety and toxicology advantages of antibody therapeutics with the power of synthetic lethality – and it is designed to ‘topple’ the most stubborn, hard-to-reach cancers.

Expand

Might take a few weeks for the fresh allocation to balance ... but it's up from there.

Would be surprised if there wasn't some juicy news towards end of 3Q or early next.

PAB Price at posting: 1.3¢ Sentiment: None Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

DVP

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

GRX

GreenX picks up prospective copper project in Germany

VMT

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Is oil undervalued?

WGX

Westgold sets its sights on top five producer status through merger with Karora

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

NXG

Cost blow-out for Rook I uranium project sees share plummet for NexGen

BOE

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

MGU

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

VMS

Venture to sniff out high-grade REE targets at Jupiter project, WA

There are more pages in this discussion • 13 more messages in this thread...

First 26 Last

Add PAB (ASX) to my watchlist

(20min delay)
Last 0.7¢		Change 0.000(0.00%)		Mkt cap ! $14.40M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
15	5382389	0.6¢

Sellers (Offers)

Price($)	Vol.	No.
0.7¢	2352699	1

View Market Depth

No.	Vol.	Price($)
15	5382389	0.006
15	7215158	0.005
10	5739000	0.004
7	6399016	0.003
3	2521000	0.002

Price($)	Vol.	No.
0.007	2352699	1
0.008	1880092	4
0.009	1133332	2
0.010	557000	3
0.011	1000000	1

Last trade - 16.12pm 02/08/2024 (20 minute delay)

PAB (ASX) Chart

Day chart unavailable

Ann: Investor update, page-26

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

GreenX picks up prospective copper project in Germany

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Is oil undervalued?

Westgold sets its sights on top five producer status through merger with Karora

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Venture to sniff out high-grade REE targets at Jupiter project, WA

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Investor update, page-26

Top Stories

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

GreenX picks up prospective copper project in Germany

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Is oil undervalued?

Westgold sets its sights on top five producer status through merger with Karora

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Venture to sniff out high-grade REE targets at Jupiter project, WA

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News